Testosterone and Type 2 Diabetes: What the Evidence Shows (2026 Guide)

Executive Summary

Type 2 diabetes and testosterone deficiency co-occur at rates that are not coincidental. Clinical studies consistently find that 25–40% of men with type 2 diabetes have total testosterone below 300 ng/dL — significantly higher than the 10–15% prevalence seen in the general male population of similar age. The American Diabetes Association (ADA) now formally recommends that men with type 2 diabetes be screened for hypogonadism, reflecting a growing clinical consensus that these conditions are mechanistically intertwined, not simply coincidental comorbidities.

The mechanistic relationship is bidirectional. Low testosterone reduces insulin-stimulated glucose disposal in skeletal muscle, promotes visceral fat accumulation that worsens insulin resistance, and impairs hepatic insulin signaling. Conversely, the chronic hyperinsulinemia of T2DM disrupts the hypothalamic-pituitary-gonadal (HPG) axis and directly impairs Leydig cell steroidogenesis. The result is a hormonal-metabolic feedback loop in which each condition worsens the other — and that testosterone replacement therapy (TRT) can interrupt at the hormonal level.

This guide covers the mechanisms linking testosterone deficiency to T2DM, the epidemiological data, the strongest clinical trial evidence for TRT in hypogonadal diabetic men, practical assessment guidance, and how TRT integrates with GLP-1 agonist therapy. For related reading, see testosterone and metabolic syndrome, testosterone and inflammation, GLP-1 and TRT together, and testosterone and weight loss.

At-a-Glance Comparison

Summary of glycemic markers, their relationship to testosterone status, and TRT's clinical effect. Evidence ratings reflect quality and volume of available human clinical data as of 2026.

How Low Testosterone Drives Type 2 Diabetes: The Mechanisms

The testosterone-T2DM connection is not simply a correlation driven by shared obesity risk. There are specific, well-characterized cellular mechanisms through which testosterone deficiency impairs glucose homeostasis — mechanisms that explain why TRT can improve glycemic control beyond what is achieved by weight management alone. Buyers searching for testosterone and type 2 diabetes usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

1. Skeletal muscle GLUT4 downregulation. Skeletal muscle is responsible for approximately 80% of insulin-stimulated glucose disposal. Testosterone acts through androgen receptors in myocytes to upregulate GLUT4 glucose transporter expression and enhance insulin receptor substrate-1 (IRS-1) signaling. In hypogonadal men, GLUT4 expression in skeletal muscle is measurably lower than in eugonadal controls — directly reducing the cell's ability to clear glucose in response to insulin. This manifests as elevated postprandial glucose, elevated fasting insulin, and elevated HOMA-IR. 2. Visceral adiposity and aromatase-driven insulin resistance. Testosterone normally suppresses visceral adipocyte differentiation. When testosterone falls, visceral fat accumulates. Visceral adipose tissue releases free fatty acids (FFAs) that impair hepatic insulin signaling and secretes pro-inflammatory cytokines (TNF-α, IL-6) that interfere with insulin receptor signaling in muscle, liver, and pancreas. Visceral fat also upregulates aromatase, converting androgens to estrogens and further suppressing testosterone — creating a self-amplifying hormonal-metabolic loop. 3. Hepatic insulin resistance. Testosterone supports hepatic insulin receptor expression and insulin-stimulated glycogen synthesis. Hypogonadism is associated with increased hepatic fat deposition (NAFLD), which is itself a major driver of hepatic insulin resistance and a precursor to the progressive gluconeogenesis dysregulation characteristic of T2DM. 4. Pancreatic beta-cell function. Emerging evidence suggests testosterone may have direct effects on pancreatic beta-cell survival and insulin secretion capacity. Androgen receptors are expressed in islet beta cells, and testosterone appears to protect against cytokine-mediated beta-cell apoptosis. Hypogonadism may therefore accelerate the progressive beta-cell loss that characterizes advancing T2DM. 5. The hyperinsulinemia feedback loop. As insulin resistance develops, the pancreas compensates with elevated insulin secretion. Chronic hyperinsulinemia directly suppresses LH pulsatility at the hypothalamic level and impairs Leydig cell steroidogenesis — further lowering testosterone. This creates a bidirectional worsening loop: low T → insulin resistance → hyperinsulinemia → lower T → more insulin resistance. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: These mechanisms are most clearly operative in men with genuine testosterone deficiency (total T consistently below 300 ng/dL with symptoms). Supraphysiological testosterone in eugonadal men does not necessarily produce proportionate glycemic benefits and carries significant risk. The mechanisms described are about restoring deficient testosterone to the physiological range. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Epidemiology: How Common Is Low Testosterone in Men with Type 2 Diabetes?

The co-occurrence of hypogonadism and T2DM in men is well-established across multiple populations and study designs. The prevalence data are robust enough that major diabetes organizations now recommend testosterone screening in men with T2DM. Buyers searching for testosterone and type 2 diabetes usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

A 2010 meta-analysis by Ding et al. in JAMA found that total testosterone was 2.0 nmol/L (58 ng/dL) lower in men with type 2 diabetes than age-matched controls — a clinically significant difference. In the Massachusetts Male Aging Study, men in the lowest testosterone quartile had a 42% increased risk of incident type 2 diabetes over 9 years compared to men in the highest quartile, after adjustment for age, BMI, and physical activity. Prevalence studies in men with established T2DM consistently find rates of hypogonadism (total T < 300 ng/dL) of 25–40%. A large UK study of 1,901 men with T2DM found that 43% had serum testosterone below 11 nmol/L (317 ng/dL), and 25% had values below 8 nmol/L (230 ng/dL) — levels associated with significant androgen deficiency. The Endocrine Society and the American Diabetes Association both now recommend routine testosterone testing in men with T2DM given this evidence base. An important nuance: obesity independently lowers testosterone through aromatase activity and hypothalamic suppression, and most men with T2DM are also obese. Controlling for BMI attenuates but does not eliminate the testosterone-diabetes association, suggesting both obesity-dependent and obesity-independent pathways. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: Not all men with T2DM and low testosterone have primary or permanent hypogonadism. Some have functional hypogonadism driven by obesity, sleep apnea, or metabolic stress. In these men, significant weight loss can normalize testosterone without lifelong TRT. Distinguishing permanent from functional hypogonadism matters for treatment decision-making. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

What Clinical Trials Show: TRT in Hypogonadal Men with T2DM

The clinical trial evidence on TRT's glycemic effects in hypogonadal diabetic men is among the most compelling in the TRT literature. Several well-designed RCTs specifically enrolled men with T2DM and demonstrated meaningful improvements in HbA1c, fasting glucose, and insulin sensitivity. Buyers searching for testosterone and type 2 diabetes usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

Hackett et al. (2016) — The Landmark T2DM RCT: This double-blind RCT enrolled 199 men with type 2 diabetes and confirmed hypogonadism (total testosterone < 10.4 nmol/L). Men were randomized to testosterone undecanoate 1,000 mg IM or placebo every 12 weeks for 30 weeks. Results: TRT reduced HbA1c by 0.4% vs placebo (p=0.038), reduced fasting glucose by 1.58 mmol/L vs placebo, reduced HOMA-IR by 1.73 vs placebo, and reduced waist circumference by 2.6 cm vs placebo. Critically, this was an additive benefit on top of existing diabetes medication — TRT was not replacing metformin or SGLT2 inhibitors, it was improving outcomes in addition to standard care. IPASS (2013, n=261): 261 testosterone-deficient men (not specifically diabetic) received testosterone undecanoate over 30 weeks. Fasting glucose reduced significantly, as did HOMA-IR, waist circumference, and total cholesterol. Metabolic improvements were largest in men who were obese or had type 2 diabetes at baseline. TRAVERSE Trial (2023–2024, n=5,204): The most important recent TRT safety and efficacy trial enrolled 5,204 men with existing cardiovascular disease or high CV risk, many of whom had T2DM. Key glycemic findings: TRT produced statistically significant reductions in HbA1c and fasting glucose vs placebo at 12 months and 24 months. No increase in major adverse cardiovascular events (MACE) — resolving the cardiovascular safety concern from earlier smaller trials. 2019 JCEM Meta-Analysis (30 RCTs, n=1,159): This systematic review pooled 30 RCTs and found TRT vs placebo produced: fasting glucose reduction of −0.50 mmol/L (−9 mg/dL), HOMA-IR reduction of −1.44, and waist circumference reduction of −2.76 cm. Effects were moderated by baseline testosterone — men with lower starting testosterone showed the most improvement. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: The glycemic benefits of TRT in RCTs are meaningful but moderate — a 0.4% HbA1c reduction is less than metformin (~1%) or SGLT2 inhibitors (~0.7%). TRT is not a replacement for diabetes medications; it is an adjunct for hypogonadal men that addresses an underlying hormonal driver of insulin resistance. Men with well-controlled T2DM and normal testosterone levels should not expect glycemic benefits from TRT. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

TRT and GLP-1 Agonists in Men with T2DM: Synergies and Sequencing

GLP-1 receptor agonists (semaglutide, tirzepatide) have transformed T2DM management with dramatic HbA1c and weight loss outcomes. For hypogonadal men, combining TRT with GLP-1 therapy addresses complementary metabolic pathways and appears to improve body composition outcomes compared to either alone. Buyers searching for testosterone and type 2 diabetes usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

GLP-1 agonists work primarily through CNS satiety signaling, delayed gastric emptying, and enhanced glucose-dependent insulin secretion. In T2DM, they reduce HbA1c by 1.0–1.6% and body weight by 10–22% depending on the agent. However, a consistent finding across GLP-1 trials is that 25–40% of total weight lost can be lean mass (skeletal muscle) in the absence of resistance training and adequate protein intake. For hypogonadal men, this lean mass loss problem is compounded by testosterone deficiency — and TRT directly addresses it. Testosterone's anabolic effects on skeletal muscle are androgen-receptor mediated and distinct from the GLP-1 mechanism. Men on TRT show greater preservation of lean mass during caloric restriction than non-TRT controls. Real-world clinic data from 2024–2025 suggest that hypogonadal men on GLP-1 + TRT combination therapy show superior body composition outcomes — more visceral fat loss, less muscle loss, better insulin sensitivity — compared to GLP-1 alone. Additionally, GLP-1-mediated caloric restriction and weight loss can transiently lower testosterone further before aromatase-mediated estrogen production decreases as visceral fat shrinks. This means some men starting GLP-1 therapy will see testosterone fall before it rises — a reason to test testosterone before initiating GLP-1 therapy and monitor it during treatment. For a detailed breakdown of this combination, see GLP-1 and TRT together and tirzepatide vs semaglutide for men. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: No published head-to-head RCTs comparing GLP-1 + TRT vs GLP-1 alone in men with T2DM exist as of early 2026. The combination rationale is mechanistically sound and observationally supported, but the magnitude of additive glycemic benefit has not been quantified in a prospective trial. The body composition benefit appears stronger and more consistent than the glycemic benefit in available data. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Clinical Assessment: Screening and Treatment Guidance for Men with T2DM

For men with type 2 diabetes, the clinical case for testosterone screening is strong enough that multiple guidelines now recommend it. Here is a practical framework for testing, interpretation, and treatment decision-making. Buyers searching for testosterone and type 2 diabetes usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

Who should be tested: The ADA and Endocrine Society recommend testosterone testing in all men with T2DM who have symptoms of androgen deficiency — decreased libido, erectile dysfunction, fatigue, depressed mood, reduced muscle mass, or difficulty achieving adequate glycemic control despite appropriate medication. Even in asymptomatic men with T2DM, some clinicians screen proactively given the high prevalence of occult hypogonadism. What to test: Morning (7–10 AM) total testosterone is the first-line screen. Testosterone follows a circadian rhythm with a peak in the morning; afternoon samples can be falsely low. If total testosterone is borderline (270–400 ng/dL), add SHBG and calculate free testosterone. Add LH and FSH to distinguish primary (testicular failure) from secondary (HPG axis suppression) hypogonadism — the distinction matters for treatment selection. Full metabolic panel including HbA1c, fasting glucose, fasting lipids, and waist circumference provides the baseline for tracking treatment response. Treatment thresholds: Total testosterone consistently below 300 ng/dL with at least one symptom supports TRT initiation in most guidelines. In men with T2DM, some clinicians consider treatment at 300–400 ng/dL when glycemic control is poor and other reversible causes have been addressed. Monitoring on TRT: Testosterone levels at 3–6 months. HbA1c at 6 months and 12 months — where improvements are most likely to be detectable. Fasting glucose, HOMA-IR, fasting lipids, and waist circumference at 6–12 months. Hematocrit at 3–6 months (level >54% requires dose reduction). PSA at baseline, 3 months, and 12 months. For telehealth TRT options that include lab work, see how to get testosterone prescribed online and best online TRT clinics compared. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: Obesity-related functional hypogonadism in men with T2DM may normalize with significant weight loss. Men who achieve meaningful weight reduction through GLP-1 therapy, bariatric surgery, or sustained lifestyle change should have testosterone retested before committing to lifelong TRT — some will recover normal testosterone function without replacement. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Internal Resources to Compare Next

Use these pages to validate assumptions before spending. Cross-checking provider model details with treatment-specific pages is the fastest way to reduce preventable cost drift in month two and month three.

Compare Providers Before You Purchase

If you have type 2 diabetes and suspect low testosterone may be contributing to poor glycemic control, a morning testosterone panel is the right first step. Our provider comparison tool helps you find clinics that include labs in their initial evaluation — so you start with data, not assumptions.

Disclosure: PeakedLabs may earn a commission from partner links. Editorial scoring and rankings remain independent.

Frequently Asked Questions

Does low testosterone cause type 2 diabetes?

Low testosterone contributes to T2DM risk through multiple mechanisms: reduced GLUT4 expression in skeletal muscle (impairing insulin-stimulated glucose disposal), increased visceral fat (worsening hepatic insulin resistance), and impaired hepatic insulin signaling. Longitudinal data show men with low testosterone are 42% more likely to develop T2DM over 9 years than men with normal testosterone. The relationship is bidirectional — T2DM also suppresses testosterone production through hyperinsulinemia-driven HPG axis disruption.

Will TRT improve my blood sugar control?

In hypogonadal men with T2DM, TRT consistently improves glycemic markers: HbA1c reductions of ~0.4% and fasting glucose reductions of ~0.50 mmol/L are reported in RCTs. These are meaningful additions to standard diabetes medications, not replacements. Eugonadal men with T2DM should not expect glycemic benefits from TRT — the benefit is specific to men with testosterone deficiency.

How common is low testosterone in men with type 2 diabetes?

Very common — 25–40% of men with T2DM have total testosterone below 300 ng/dL, compared to 10–15% in the general male population of similar age. Major diabetes organizations (ADA, Endocrine Society) now recommend testosterone screening in men with T2DM based on this evidence.

What does the best evidence show about TRT and HbA1c?

Hackett et al. (2016) — the largest RCT specifically targeting men with T2DM and hypogonadism (n=199) — found TRT reduced HbA1c by 0.4% vs placebo over 30 weeks, along with significant reductions in fasting glucose and HOMA-IR. The TRAVERSE trial (n=5,204) confirmed sustained HbA1c reductions at 12 and 24 months. A 2019 meta-analysis of 30 RCTs found a mean fasting glucose reduction of 0.50 mmol/L with TRT.

Is TRT safe for men with type 2 diabetes and heart disease?

The TRAVERSE trial (2023–2024, n=5,204, 33-month follow-up) specifically enrolled men with high cardiovascular risk, many with T2DM, and found TRT did not increase major adverse cardiovascular events (MACE) vs placebo. TRT did show increased rates of pulmonary embolism and atrial fibrillation in TRAVERSE, which requires individualized risk assessment in men with clotting or arrhythmia history. For most hypogonadal men with T2DM and standard cardiovascular risk, the TRAVERSE data provide meaningful reassurance.

Should men with type 2 diabetes taking GLP-1 agonists check testosterone?

Yes — testing testosterone before and during GLP-1 therapy is increasingly recommended. GLP-1-induced caloric restriction can transiently lower testosterone through HPG axis suppression before the visceral fat loss eventually reduces aromatase activity and allows testosterone to recover. Men with low testosterone on GLP-1 therapy also lose proportionally more lean mass during weight loss compared to men with normal testosterone — TRT can protect against this.

What testosterone level should men with T2DM aim for?

TRT is typically indicated when total testosterone is consistently below 300 ng/dL with symptoms. Most TRT protocols target a mid-normal range of 500–700 ng/dL total testosterone. Free testosterone is often more clinically relevant in men with elevated or suppressed SHBG. The goal is restoration to physiological normal — not supraphysiological elevation — as metabolic benefits are specific to correcting deficiency.

Can losing weight raise testosterone in men with T2DM?

Yes — significant weight loss (15%+ body weight) can normalize testosterone in men with obesity-driven functional hypogonadism. GLP-1 agonists, SGLT2 inhibitors (through weight and insulin effects), and bariatric surgery all demonstrate testosterone increases following substantial weight reduction. Men who achieve significant weight loss should retest testosterone before committing to lifelong TRT — some will recover normal testosterone function without replacement.

Where can men with type 2 diabetes get testosterone testing?

Primary care physicians and endocrinologists can order testosterone testing. For a more direct path, many telehealth TRT clinics include comprehensive hormone and metabolic labs as part of their intake process. See our guide to how to get testosterone prescribed online and the provider comparison tool to find clinics that include lab work in their initial evaluation.

How long does it take TRT to improve blood sugar in diabetic men?

Fasting glucose and HOMA-IR improvements are typically measurable within 3–6 months of TRT initiation. HbA1c improvements follow the 90-day red blood cell turnover cycle — meaningful HbA1c changes are generally detectable at 6 months. Waist circumference and visceral fat reductions often follow a 6–12 month timeline. Sustained improvements typically require 12–24 months of TRT combined with resistance training and dietary support.

Does TRT replace diabetes medications?

No — TRT is not a replacement for metformin, SGLT2 inhibitors, GLP-1 agonists, or other diabetes medications. It is an adjunct that addresses an underlying hormonal driver of insulin resistance in men who are both hypogonadal and diabetic. In the Hackett (2016) trial, TRT improved glycemic control on top of existing diabetes medications — the two approaches are complementary, not competitive.